Vanda’s antisense therapy wins FDA rare pediatric disease designation for CMT2S

Washington, DC-based Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the US FDA has granted Rare Pediatric Disease Designation (RPDD) to VCA-894A, an investigational antisense oligonucleotide (ASO) therapy targeting a cryptic splice site variant within the IGHMBP2 gene, for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S). The designation was granted by the FDA’s Office of Orphan Products Development and Office of Pediatric Therapeutics.

The RPDD matters primarily for its downstream commercial implication: upon approval of a qualifying marketing application, Vanda may become eligible to receive a Priority Review Voucher (PRV) under the Rare Pediatric Disease Priority Review Voucher program. PRVs have recently traded at disclosed values of USD 150–205 million. Eligibility is not guaranteed and will be assessed at the time of any future marketing application review.

VCA-894A is a 2′-O-methoxyethyl (MOE) phosphorothioate oligonucleotide sodium salt. It functions by binding to an aberrant cryptic splice site within IGHMBP2 pre-mRNA, correcting the pathogenic splicing event that underlies CMT2S in the specific patient for whom it was designed. The MOE phosphorothioate backbone confers nuclease resistance and enhanced target binding affinity — chemical properties shared with approved ASO therapies delivered to the central nervous system.

CMT2S is an inherited axonal neuropathy caused by pathogenic variants in IGHMBP2, a gene encoding immunoglobulin mu-binding protein 2. Loss of functional IGHMBP2 leads to alpha-motor neuron degeneration and progressive peripheral nervous system deterioration, manifesting in early childhood as distal muscle weakness, sensory impairment, and loss of motor function. The FDA determined that CMT2S qualifies as a rare pediatric disease because its serious manifestations primarily affect individuals from birth through 18 years of age and the condition meets the statutory definition of a rare disease, with a global prevalence estimated at fewer than 1 in 1,000,000.

VCA-894A is being developed for a single patient first diagnosed at age five with a unique IGHMBP2 variant not documented in any other individual. The program represents an n-of-1 precision medicine approach, designed to correct a patient-specific genetic lesion rather than a shared population-level mutation.

The AllSci BriefSystematic R&D and deal news. Daily.

VCA-894A had previously received Orphan Drug Designation from the FDA for CMT2S, as noted in Vanda’s February 2025 publication announcement. The Investigational New Drug (IND) application was cleared by the FDA in January 2024, and Vanda announced first-in-human dosing in June 2025, making VCA-894A one of the few bespoke ASO programs to reach clinical evaluation in a single patient.

Strategic significance for Vanda

VCA-894A sits within Vanda’s broader precision medicine platform, which also includes VGT-1849A, a selective ASO-based JAK2 inhibitor that received Orphan Drug Designation for polycythemia vera in December 2024. The CMT2S program is operationally small — designed for one patient — but serves as a proof-of-concept vehicle for Vanda’s ASO platform capabilities and, if it ultimately meets approval criteria, would yield a PRV that could be monetized or applied to a future marketing application for a different product.

The July 2026 RPDD adds to the existing Orphan Drug Designation for VCA-894A and reinforces the FDA’s formal recognition of CMT2S as a serious pediatric condition. Whether the first-in-human study, which enrolled its single patient in June 2025, will generate data sufficient to support a future marketing application remains to be seen.


This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/